Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16228778 | 1.00 | BTK (0.62) | BTKALDH1A1POLBTDP1KMT2A | |
| SCHEMBL5842351 | 0.89 | BTK (0.53) | BTKALDH1A1POLBTDP1KMT2A | |
| SCHEMBL14826605 | 0.89 | BTK (0.53) | BTKALDH1A1POLBTDP1KMT2A | |
| SCHEMBL16876437 | 0.89 | BTK (0.53) | BTKALDH1A1POLBTDP1KMT2A | |
| SCHEMBL14814213 | 0.89 | BTK (0.53) | BTKALDH1A1POLBTDP1KMT2A | |
| SCHEMBL20116642 | 0.89 | KMT2A (0.59) | BTKALDH1A1POLBTDP1KMT2A | |
| SCHEMBL14750015 | 0.89 | BTK (0.66) | BTKALDH1A1POLBTDP1KMT2A | |
| SCHEMBL19046169 | 0.82 | BTK (0.49) | BTKALDH1A1POLBTDP1KMT2A | |
| SCHEMBL1269684 | 0.82 | CYP3A4 (0.67) | ALDH1A1KMT2AMAPK1CYP3A4CYP2C19 | |
| SCHEMBL16963946 | 0.82 | BTK (0.48) | BTKALDH1A1POLBTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655069-A1 | PYRIDAZINES AS SARM1 INHIBITORS | Disarm Therapeutics, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024158775-A1 | PYRIDAZINES AS SARM1 INHIBITORS | DISARM THERAPEUTICS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| CN-108473498-B | Pyrazolo [1,5a ] pyrimidine derivatives as IRAK4 modulators | 豪夫迈·罗氏有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200207809-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-RE47302-E1 | Peptide epoxyketone immunoproteasome inhibitors | ONYX THERAPEUTICS INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-9434761-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9242984-B2 | Pyrazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150191461-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20140336106-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-8039507-B2 | Therapeutic substituted gamma lactams | ALLERGAN, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-7705001-B2 | Therapeutic substituted gamma lactams | ALLERGAN, INC (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090239867-A1 | THERAPEUTIC SUBSTITUTED GAMMA LACTAMS | ALLERGAN, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| WO-2009117465-A1 | SUBSTITUTED GAMMA LACTAMS AS PROSTAGLANDIN EP2 AGONISTS | ALLERGAN, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20080255220-A1 | For treating inflammatory bowel disease, glaucoma or ocular hypertension, asthma; 7-[(3R*,4R*)-2-Oxo-4-((E)-3-oxo-oct-1-enyl)-pyrrolidin-3-yl]-hept-5-ynoic acid methyl ester; prostaglandin EP2 agonists | ALLERGAN, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2007005176-A1 | PYRROLIDINONES FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191461-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | SYK, BTK, LCK | BTK 2/4885ALDH1A1 2112/4885POLB 2581/4885 |
| US-11078233-B2 | Tripeptide epoxy ketone protease inhibitors | PREP, CTRL, ENPEP | BTK 2979/4885ALDH1A1 1694/4885POLB 3818/4885 |
| US-20090239867-A1 | THERAPEUTIC SUBSTITUTED GAMMA LACTAMS | DDO, DAO, GLA | BTK 207/4885ALDH1A1 1689/4885POLB 1618/4885 |
| US-20200207809-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | BTK 2979/4885ALDH1A1 1694/4885POLB 3818/4885 |
| US-20140336106-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | BTK 2979/4885ALDH1A1 1694/4885POLB 3818/4885 |
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | PREP, CTRL, ENPEP | BTK 2979/4885ALDH1A1 1694/4885POLB 3818/4885 |
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK1, IRAK4, IRAK2 | BTK 131/4885ALDH1A1 1115/4885POLB 2188/4885 |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK1, IRAK4, IRAK2 | BTK 131/4885ALDH1A1 1146/4885POLB 2258/4885 |
| US-20080255220-A1 | For treating inflammatory bowel disease, glaucoma or ocular hypertension, asthma; 7-[(3R*,4R*)-2-Oxo-4-((E)-3-oxo-oct-1-enyl)-pyrrolidin-3-yl]-hept-5-ynoic acid methyl ester; prostaglandin EP2 agonists | PTGIR, PTGIS, PTGER1 | BTK 2999/4885ALDH1A1 1393/4885POLB 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.